Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 3Neoplasm Metastasis 2Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Urothelial Carcinoma 1Melanoma 1Lymphatic Metastasis 1Head and Neck Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 10 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

Fluorouracil 7Oxaliplatin 6Nivolumab 5Leucovorin 5fludarabine 4Paclitaxel 4Docetaxel 4Cyclophosphamide 4Capecitabine 4zimberelimab 3pembrolizumab 3aldesleukin 3Trastuzumab 3Ramucirumab 3ulixertinib 2trastuzumab deruxtecan 2fludarabine phosphate 2Specimen Handling 2Irinotecan 2Cisplatin 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1toripalimab 1tislelizumab 1sodium propionate 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × avelumab × 30 days × Clear all
NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.

Phase 1/2 Recruiting
159 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡